Clinical Trials
50 trialsPreoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
University of California, San Diego
ATEZOGIST
Centre Leon Berard
PALANGI3
Centre Oscar Lambret
Imatinib TDM in GIST
University of Kentucky
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Asan Medical Center
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
Helsinki University Central Hospital
Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM
First Affiliated Hospital, Sun Yat-Sen University
Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes
First Affiliated Hospital, Sun Yat-Sen University
Ipilimumab and Imatinib Mesylate in Advanced Cancer
M.D. Anderson Cancer Center
ImadGist
Centre Leon Berard
Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
Asan Medical Center
Entacapone Combination With Imatinib for Treatment of GIST
Xiangya Hospital of Central South University
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
Centre Leon Berard
PIRKER
Fujian Medical University Union Hospital
GISTs
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
EMMBKM
Xijing Hospital
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Asan Medical Center
PDR001 Plus Imatinib for Metastatic or Unresectable GIST
Asan Medical Center
ZJGIST-01
First Affiliated Hospital of Zhejiang University
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
Asan Medical Center
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
Asan Medical Center
Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment
Shanghai Zhongshan Hospital
Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study to Evaluate Imatinib in Desmoid Tumors
Heidelberg University
Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients
University of Utah
Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
UNICANCER
GIGIST
Assistance Publique Hopitaux De Marseille
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Duke University
Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors
Central European Cooperative Oncology Group
Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors
Asan Medical Center
Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Peking University
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
Sarcoma Alliance for Research through Collaboration
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
Duke University
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Duke University
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Duke University
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Duke University
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
University of Virginia
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
Duke University
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
Sarcoma Alliance for Research through Collaboration
Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Technical University of Munich
Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
Scandinavian Sarcoma Group
Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors
Vanderbilt-Ingram Cancer Center
Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
M.D. Anderson Cancer Center
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)
Dermatologic Cooperative Oncology Group
Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor
City of Hope Medical Center
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
Maisonneuve-Rosemont Hospital